Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

OBJECTIVE: To assess the efficacy and safety of tocilizumab (TCZ) plus methotrexate/placebo (MTX/PBO) over 2 years and the course of disease activity in patients who discontinued TCZ due to sustained remission. METHODS: ACT-RAY was a double-blind 3-year trial. Patients with active rheumatoid arthrit...

Descripción completa

Detalles Bibliográficos
Autores principales: Huizinga, T W J, Conaghan, Philip G, Martin-Mola, Emilio, Schett, Georg, Amital, Howard, Xavier, Ricardo M, Troum, Orrin, Aassi, Maher, Bernasconi, Corrado, Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283697/
https://www.ncbi.nlm.nih.gov/pubmed/25169728
http://dx.doi.org/10.1136/annrheumdis-2014-205752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283697/
https://www.ncbi.nlm.nih.gov/pubmed/25169728
http://dx.doi.org/10.1136/annrheumdis-2014-205752

Ejemplares similares